Steven Cohen’s Kalaris Therapeutics KLRS Stock Holding History

Steven Cohen’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-259	Closed	-$20.3K	–	2938
2023 Q2	$20.3K	Sell	259 -109	-30%	-$10.4K	﹤0.01%	1784
2023 Q1	$33.4K	Buy	+368	New	+$46.9K	﹤0.01%	1870

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's KLRS Position: Q3 2023 in Review

Steven Cohen sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 259 shares — an estimated $20.3K sold.

Steven Cohen first reported a position in KLRS in Q1 2023 and held it in 2 quarters. The position peaked at $33.4K in Q1 2023. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

Steven Cohen reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
Steven Cohen sold 259 Kalaris Therapeutics shares in Q3 2023, an estimated $20.3K.
Steven Cohen first reported a position in Kalaris Therapeutics in Q1 2023 and held it in 2 quarters.
Steven Cohen's Kalaris Therapeutics position peaked at $33.4K in Q1 2023.
90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.